First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis

Affiliations

• ¹ Division of Experimental Oncology Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy.
• ² Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada.
• ³ Weill Cornell Medicine New York New York USA.
• ⁴ Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Miami Florida USA.
• ⁵ Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA.
• ⁶ Biostatistics, Everest Clinical Research Owings Mills Maryland USA.
• ⁷ AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA.
• ⁸ Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA.